SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Durata Therapeutics, Inc. And Encourages ...
10 Outubro 2014 - 6:25PM
Business Wire
The securities litigation law firm of Brower Piven, A
Professional Corporation, has commenced an investigation into
possible breaches of fiduciary duty and other violations of state
law by the Board of Directors of Durata Therapeutics, Inc. (NASDAQ:
DRTX), (“Durata” or the “Company”) relating to the proposed buyout
of the Company by Actavis plc (“Actavis”).
On October 6, 2014, Durata and Actavis announced that they have
entered into a definitive merger agreement pursuant to which
Actavis will acquire Durata in a transaction valued at
approximately $675 million. Under the terms of the transaction,
Durata shareholders are anticipated to receive $23.00 in cash for
each share of Durata stock they own, as well as contingent value
rights (“CVRs”) entitling the holder to receive additional cash
payments of up to $5.00 per share in the event certain
developmental and/or commercial milestones are met.
The firm’s investigation seeks to determine, among other things,
whether the Company’s Board of Directors breached their fiduciary
duties by failing to maximize shareholder value before agreeing to
enter into the transaction, and whether Actavis is underpaying for
Durata shares.
If you currently own common stock of Durata and would like to
learn more about the investigation being conducted by Brower Piven,
without cost or obligation to you, please visit our website at
http://www.browerpiven.com/currentinvestigations.html. You may also
request more information by contacting Brower Piven either by email
at hoffman@browerpiven.com or by telephone at (410) 415-6616.
Attorneys at Brower Piven have extensive experience in
litigating securities and other class action cases and have been
advocating for the rights of shareholders since the 1980s.
Brower Piven, A Professional CorporationCharles J. Piven,
410-415-66161925 Old Valley RoadStevenson, Maryland
21153hoffman@browerpiven.com
(MM) (NASDAQ:DRTX)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
(MM) (NASDAQ:DRTX)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
Notícias em tempo-real sobre (MM) da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Durata Therapeutics, Inc. (MM)